CD200

23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Mittwoch, April 24, 2024
Safety, Cancer, Genetics, Abstract, 23andMe, Research, Immune tolerance, CD200, Immunodeficiency, Patient, DOK2, Therapy, Ovarian cancer, SAN, Vaccine

23andMe will present clinical data, including preliminary efficacy and exploratory biomarker analyses, for the neuroendocrine and ovarian cancer patient cohorts in the Phase 2a portion of its ongoing Phase 1/2a clinical trial.

Key Points: 
  • 23andMe will present clinical data, including preliminary efficacy and exploratory biomarker analyses, for the neuroendocrine and ovarian cancer patient cohorts in the Phase 2a portion of its ongoing Phase 1/2a clinical trial.
  • 23andMe scientists discovered the target for 23ME-00610 through the Company’s proprietary database of human genetic and health information.
  • 23andMe has more than 15 million genotyped customers, roughly 80 percent of whom consent to participate in research.
  • Title: Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort.

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Freitag, April 5, 2024
23andMe, Prevalence, Plasma, Genetics, NKG2D, Patient, SAN, Neoplasm, Data, Endothelium, Immunodeficiency, Cancer, Adenocarcinoma, PBMC, Biology, CD200, AACR, Therapy, Immunohistochemistry, NK, Carcinoma, The Cancer Genome Atlas, PD-1, Vaccine

Data also show soluble ULBP6 is a dominant immunosuppressor compared to other soluble NKG2D ligands due to its highest binding affinity to NKG2D among all NKG2D ligands.

Key Points: 
  • Data also show soluble ULBP6 is a dominant immunosuppressor compared to other soluble NKG2D ligands due to its highest binding affinity to NKG2D among all NKG2D ligands.
  • ULBP6 is a stress-induced ligand that is upregulated on the surface of cancer cells and binds to the activating immunoreceptor NKG2D found on NK and T cells.
  • The presentations will be available on the 23andMe Investor Relations and Therapeutics websites on April 8, 2024.
  • Title: 23ME-01473, a novel anti-ULBP6/2/5 monoclonal antibody, reinvigorates anti-tumor NK cell function through NKG2D and FcγRIIIa activation

Pioneer Launches Venture Group to Fund the Fight Against Rare Pediatric Brain Cancer

Retrieved on: 
Mittwoch, Dezember 6, 2023
Arm, Attention, Koenen, Research, CD200, Radiation, Immune system, Therapy, Pediatrics, University, Glioblastoma, Diffuse intrinsic pontine glioma, OX2, FDA, Child, Peter Westerhaus, MD, Diagnosis, Pioneer, Doctor of Philosophy, Immunotherapy, DIPG, Children's Hospital, Mutation, Cell, Life, Hospital, Pharmaceutical industry, Birth control, Charles Moertel

"We've been working to start a venture arm for more than five years now," said Pioneer founder and co-owner, Brian Westerhaus.

Key Points: 
  • "We've been working to start a venture arm for more than five years now," said Pioneer founder and co-owner, Brian Westerhaus.
  • (Koenen is a partner and co-owner at Pioneer Management Consulting and Pioneer Ventures Group.)
  • It gets less than 4% of all cancer research dollars available, and almost none of that goes to rare types, like DIPG.
  • To donate to the pediatric trial at Children's Hospital in Minnesota, please contact Teri Cannon [email protected]

23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies

Retrieved on: 
Dienstag, Februar 28, 2023
MSI-H, Safety, Therapy, Doctor of Philosophy, MD, Helios Techno Holding Co., Ltd., CD200, Research, Myelocyte, Patient, Genetics, Progression-free survival, Neoplasm, Carcinoma, ORR, SAN, Renal cell carcinoma, 23andMe, PFS, Cancer, Primary peritoneal carcinoma, Genome, Pharmaceutical industry, Medical imaging, Vaccine, CD200R1

A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.

Key Points: 
  • A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.
  • The Phase 2a component will include assessment of objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in the expansion cohorts.
  • 23andMe anticipates that it will present an update from the Phase 1 dose escalation portion of the study at a scientific conference this year.
  • 23andMe scientists study the aggregate, de-identified genetics of these participants, alongside more than 4 billion self-reported health data points.

23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting

Retrieved on: 
Montag, November 7, 2022
Doctor of Philosophy, Patient, Neoplasm, Immune tolerance, Research, Sumathi Best Television Current Reporting Award, MSI-H, Therapy, Growth, Maintenance, SAN, PLOS, PLOS Genetics, Genetics, GLOBE, Squamous cell carcinoma, Safety, Pharmacokinetics, Securities Exchange Act of 1934, Poster, Terminology, Nature Genetics, Immunotherapy, Securities Act of 1933, 23andMe, Annual general meeting, Annual report, U.S. Securities and Exchange Commission, Cancer, Genome, Helios Techno Holding Co., Ltd., Security (finance), Society, CD200, SITC, MD, Nature, Myelocyte, Primary peritoneal carcinoma, Pharmaceutical industry, Vaccine, CD200R1

A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.

Key Points: 
  • A cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies will also be enrolled.
  • 23andMe has more than 13 million genotyped customers, over 80% of whom consent to participate in research.
  • 23andMe scientists study the aggregate, de-identified genetics of these participants, alongside more than 4 billion self-reported health data points.
  • Title: A Phase 1 Dose Escalation and Expansion Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies.

23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting

Retrieved on: 
Mittwoch, Oktober 5, 2022
SAN, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Therapy, Growth, Neoplasm, SITC, Annual report, Patient, Security (finance), Annual general meeting, Immunotherapy, Securities Act of 1933, CD200, Company, Immune tolerance, Myelocyte, Society, Pharmacokinetics, Securities Exchange Act of 1934, Safety, Genetics, GLOBE, Genome, Helios Techno Holding Co., Ltd., Maintenance, Terminology, FDA, Pharmaceutical industry, Vaccine, CD200R1

Included in the presentation will be details on the expansion phase of the study (part B) in patients with specific types of advanced solid tumors.

Key Points: 
  • Included in the presentation will be details on the expansion phase of the study (part B) in patients with specific types of advanced solid tumors.
  • Title: A Phase 1 Dose Escalation and Expansion Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies.
  • 23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future.
  • 23ME-00610 is a high-affinity humanized monoclonal antibody that is designed to bind to the CD200R1 receptor and prevent the interaction of CD200 and CD200R1.

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

Retrieved on: 
Mittwoch, September 7, 2022
Inflammation, Irritant, COVID-19, Pharmacokinetics, Autoimmune disease, Atopic dermatitis, Research, Dermatitis, Degenerative disease, Immune tolerance, Hyperkinesia, Disease, U.S. Securities and Exchange Commission, Risk, Incidence, Maintenance, Burling, Rash, LinkedIn, Skin, Homeostasis, Half-life, SEC, CD200, Allergen, Myelocyte, GLOBE, Nasdaq, FDA, Twitter, Knowledge, AD, Face, Dermatology, Clinical trial, Acquisition, Industry, Patient, Vaccine, Pharmaceutical industry, Risk management, Facebook

Ducentis lead asset is DS-234, a fusion protein that is a highly selective and potent agonist of the CD200 receptor (CD200R).

Key Points: 
  • Ducentis lead asset is DS-234, a fusion protein that is a highly selective and potent agonist of the CD200 receptor (CD200R).
  • Given the early-stage nature of the DS-234 program, the Ducentis acquisition is not expected to have a material impact on Arcutis financial plans.
  • Ducentis Biotherapeutics is a pre-clinical stage biotech company aiming to develop novel therapies for autoimmune disease patients with poor treatment options.
  • This press release contains "forward-looking" statements, including, among others, statements regarding Arcutis proposed acquisition of Ducentis, including the prospects for development of Ducentis programs.

23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors

Retrieved on: 
Donnerstag, Januar 6, 2022
23andMe, Therapy, Safety, Drug discovery, Lijun International Pharmaceutical (Holding) Co. Ltd., ECOG, Drug Quality and Security Act, DOK2, Research, Genetics, Patient, CA, Pharmacokinetics, Cancer, Securities Exchange Act of 1934, Immune tolerance, Database, U.S. Securities and Exchange Commission, Neoplasm, Publication, Security (finance), Disease, CEO, CD200, SEC, FDA, Genome, Degenerative disease, Myelocyte, GLOBE, Terminology, Securities Act of 1933, Machine learning, Probability, Maintenance, Vaccine, Pharmaceutical industry, CD200R1

SUNNYVALE, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-00610 for the treatment of advanced solid tumors. 23ME-00610 is 23andMe’s first wholly-owned immuno-oncology (I/O) antibody to enter the clinic. The target for the new investigational antibody, CD200R1, was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey database.

Key Points: 
  • The target for the new investigational antibody, CD200R1, was identified as a promising immuno-oncology target through 23andMes proprietary genetic and health survey database.
  • This is an important milestone for 23andMe in our mission to help people access, understand and benefit from the human genome, said Anne Wojcicki, CEO and co-founder, 23andMe.
  • The Phase 1 clinical trial is designed to evaluate the safety, tolerability and pharmacokinetics of 23ME-00610 in patients with locally advanced or metastatic solid tumors whose disease has progressed after standard of care treatment.
  • Using its genetic data, 23andMe can identify immune-related genes that are expected to have an impact on cancer biology.